Mutation in the factor II gene
Material: Blood
Test price: PLN 210
Waiting time for results: result after 21 working days
Reservation:
Test price: PLN 210
Waiting time for results: result after 21 working days
Reservation:
- Check the opening hours of the collection point and where an appointment is required.
Preparation for the examination
General
- The material for testing is blood.
- The patient does not need to fast. It is recommended to drink a glass of water approximately 30 minutes before the examination.
Important
Samples brought from outside are not accepted for testing.
Description
The test is performed to assess the risk and/or causes of venous thromboembolism.
Prothrombin is a plasma protein that is activated by damage to blood vessels and participates in the blood clotting process. The 20210a mutation in the prothrombin gene leads to increased synthesis and accumulation in the blood, which increases the risk of thromboembolism (venous and arterial thrombosis, heart attack, stroke). The increased risk of blood clots is also significant for pregnant women. Carrying a prothrombin gene mutation significantly increases the risk of spontaneous miscarriages in the first trimester and numerous pregnancy abnormalities in the third trimester, such as placental abruption and fetal growth restriction.
It is estimated that the risk of thromboembolism in individuals with the 20210a prothrombin gene mutation increases two- to three-fold, and even 10- to 20-fold when combined with the Factor V Leiden gene mutation. Other acquired prothrombotic factors, such as
pregnancy,
hormone replacement therapy,
oral contraception
, or surgery, further increase the risk of symptoms.
Testing for the 20210a prothrombin gene mutation and Factor V Leiden is recommended when the first episode of venous or arterial thrombosis occurred at a relatively young age (under 50 years of age) or in an unusual area of the body.
The test may also be ordered if the patient has a family history of recurrent thrombotic events.
The test is performed using molecular biology techniques.
Prothrombin is a plasma protein that is activated by damage to blood vessels and participates in the blood clotting process. The 20210a mutation in the prothrombin gene leads to increased synthesis and accumulation in the blood, which increases the risk of thromboembolism (venous and arterial thrombosis, heart attack, stroke). The increased risk of blood clots is also significant for pregnant women. Carrying a prothrombin gene mutation significantly increases the risk of spontaneous miscarriages in the first trimester and numerous pregnancy abnormalities in the third trimester, such as placental abruption and fetal growth restriction.
It is estimated that the risk of thromboembolism in individuals with the 20210a prothrombin gene mutation increases two- to three-fold, and even 10- to 20-fold when combined with the Factor V Leiden gene mutation. Other acquired prothrombotic factors, such as
pregnancy,
hormone replacement therapy,
oral contraception
, or surgery, further increase the risk of symptoms.
Testing for the 20210a prothrombin gene mutation and Factor V Leiden is recommended when the first episode of venous or arterial thrombosis occurred at a relatively young age (under 50 years of age) or in an unusual area of the body.
The test may also be ordered if the patient has a family history of recurrent thrombotic events.
The test is performed using molecular biology techniques.
Preparation and development of material (applies only to contractors)
982
